Macrophage Therapeutics

13 articles about Macrophage Therapeutics

• Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty

  6/24/2021

  Navidea Biopharmaceuticals, Inc. , today announced that on June 23, 2021, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware (the “Court”) ruled in favor of Navidea’s wholly-owned subsidiary, Macrophage Therapeutics, Inc.

• Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York

  12/30/2019

  Navidea Biopharmaceuticals, Inc. announced that on December 26, 2019, the United States District Court, Southern District of New York ruled on several motions related to Navidea and its majority-owned subsidiary, Macrophage Therapeutics, Inc. and Dr. Michael Goldberg that substantially limited the claims that Dr. Goldberg can pursue against Navidea and MT.

• Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property

  6/13/2019

  On June 12, 2019, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware issued an oral ruling granting the motion of Macrophage Therapeutics, Inc. (“MT”), a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), to declare as void certain transactions putatively authorized by MT’s former Chief Executive Officer

• Navidea And Macrophage Therapeutics To Provide Development Program Update

  5/3/2016

• Navidea And Macrophage Therapeutics To Provide Business Update

  4/15/2016

• Macrophage Therapeutics Produces First Two Immunoconstructs

  9/25/2015

• Navidea And Macrophage Therapeutics To Host Post-International KSHV Conference Summary Webcast / Call

  7/7/2015

• Navidea And Macrophage Therapeutics To Host Post-International KSHV Conference Summary Webcast

  7/6/2015

• BIO2015: Macrophage Therapeutics To Present At BIO2015 Conference

  6/15/2015

• BIND Therapeutics And Macrophage Therapeutics Announce Collaboration To Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform

  6/11/2015

• BIND Therapeutics And Macrophage Therapeutics Announce Collaboration To Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform

  6/11/2015

• Macrophage Therapeutics Announces Manocept Results In Kaposi’s Sarcoma Studies To Be Presented At The AACR

  4/15/2015

• Macrophage Therapeutics To Expand Efforts Into CNS Diseases

  3/23/2015